Shopping Cart 0
Cart Subtotal
USD 0

Calliditas Therapeutics AB (CALTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase

Details

Summary

Calliditas Therapeutics AB (Calliditas Therapeutics), formerly Pharmalink AB is a pharmaceutical company that develops, identifies, and commercializes pharmaceutical products for niche indications. The company's pipeline products include Busulipo that is under Phase II clinical trials and Nefecon for IgA Nephritis that is under Phase II clinical trials. Its pipeline product also comprises Xepol XP-28 that is used for the treatment of post-polio syndrome and is under pre-license sales. Calliditas Therapeutics also partners with medical research institutions such as the Karolinska Institute and Uppsala University. The company offers its products and services across Sweden. Calliditas Therapeutics is headquartered in Stockholm, Sweden.

Calliditas Therapeutics AB (CALTX)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Calliditas Therapeutics AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deal Details 10

Asset Purchase 10

Pharmalink Acquires Anti-Inflammatory Drug from Synartro 10

Venture Financing 11

Pharmalink Raises USD12 Million in Financing 11

Pharmalink Raises USD 15 Million In Series C Financing 12

Pharmalink Secures USD 5.1 Million In Series B Financing 14

Equity Offering 15

Calliditas Therapeutics Prices IPO for USD75 Million 15

Pharmalink Plans IPO 16

Calliditas Therapeutics AB-Key Competitors 17

Calliditas Therapeutics AB-Key Employees 18

Calliditas Therapeutics AB-Locations And Subsidiaries 19

Head Office 19

Recent Developments 20

Corporate Communications 20

Jun 29, 2018: Nasdaq Stockholm Welcomes Calliditas Therapeutics to the Main Market 20

Aug 24, 2017: Thomas Eklund New Chairman of Pharmalink 21

Aug 15, 2017: Pharmalink strengthens its management team. Appoints new Chief Financial Officer and head of communications 22

Jan 09, 2017: Pharmalink strengthens board with appointment of Maria Carell as Chair 23

Other Significant Developments 24

Nov 15, 2017: Pharmalink is renamed Calliditas Therapeutics 24

Appendix 25

Methodology 25

About GlobalData 25

Contact Us 25

Disclaimer 25


List Of Figure

List of Figures

Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8


List Of Table

List of Tables

Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Calliditas Therapeutics AB, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Calliditas Therapeutics AB, Deals By Therapy Area, 2012 to YTD 2018 8

Calliditas Therapeutics AB, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9

Pharmalink Acquires Anti-Inflammatory Drug from Synartro 10

Pharmalink Raises USD12 Million in Financing 11

Pharmalink Raises USD 15 Million In Series C Financing 12

Pharmalink Secures USD 5.1 Million In Series B Financing 14

Calliditas Therapeutics Prices IPO for USD75 Million 15

Pharmalink Plans IPO 16

Calliditas Therapeutics AB, Key Competitors 17

Calliditas Therapeutics AB, Key Employees 18

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com